Prosecution Insights
Last updated: November 20, 2026
Application No. 18/847,164

SPLEEN TYROSINE KINASE INHIBITOR, COMPOSITION, AND METHODS OF USE

Non-Final OA §102§103§112
Filed
Sep 13, 2024
Priority
Mar 14, 2022 — provisional 63/319,486 +2 more
Examiner
SCHMITT, MICHAEL J
Art Unit
1629
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Purdue Research Foundation
OA Round
1 (Non-Final)
57%
Grant Probability
Moderate
1-2
OA Rounds
8m
Est. Remaining
77%
With Interview

Examiner Intelligence

Grants 57% of resolved cases
57%
Career Allowance Rate
378 granted / 664 resolved
-3.1% vs TC avg
Strong +20% interview lift
Without
With
+19.9%
Interview Lift
resolved cases with interview
Typical timeline
2y 10m
Avg Prosecution
34 currently pending
Career history
704
Total Applications
across all art units

Statute-Specific Performance

§101
4.0%
-36.0% vs TC avg
§103
36.9%
-3.1% vs TC avg
§102
15.3%
-24.7% vs TC avg
§112
21.6%
-18.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 664 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Claims 1-2, 6, 9, 11, 15-16, 18, 24-25, 30, 32, 36-37, 41-42, 44, 47, and 49-50 are pending. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority The instant application filed 09/13/2024 is a National Stage entry of PCT/US2023/064326, International Filing Date: 3/14/2023. PCT/US2023/064326 Claims Priority from Provisional Application 63398599, filed 8/17/2022. PCT/US2023/064326 Claims Priority from Provisional Application 63319486, filed 3/14/2022. Information Disclosure Statement The Information Disclosure Statements (IDS) submitted on 9/13/2024 and 6/10/2026 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the Information Disclosure Statements are being considered by the Examiner. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 16 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 16 further limits the substituent of the C Ring. Claim 1 requires PNG media_image1.png 106 70 media_image1.png Greyscale where Z is: PNG media_image2.png 112 546 media_image2.png Greyscale Claim 16 states: PNG media_image3.png 200 664 media_image3.png Greyscale This structure does not have antecedent basis in claim 1, the Q group is not further limiting and is broader than claim 1. As such claim 16 is indefinite. Claim 30 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 30 is dependent on claim 1 and limits the compound to several compounds which cannot be derived from claim 1, and therefore they lack antecedent basis (or are not further limiting). For example: PNG media_image4.png 196 208 media_image4.png Greyscale This compound’s C ring is substituted with an “alcohol substituted alkyl” group and a “methyl” group. Applicant states in claim 1 that the C ring must have a first substituent comprising: PNG media_image5.png 353 640 media_image5.png Greyscale While both substituents can be the “optional” given the comprising language, neither meets the required “first substituent” defined by the claim. As such this structure in claim 30 is indefinite. The following compounds in claim 30 have the same problem: PNG media_image6.png 184 190 media_image6.png Greyscale PNG media_image7.png 204 210 media_image7.png Greyscale Claim 32 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 32 is dependent on claim 1 and limits the compound to a compound which cannot be derived from claim 1 and therefore lacks antecedent basis (or are not further limiting). Compound: PNG media_image8.png 210 244 media_image8.png Greyscale This compound is substituted with “alcohol substituted alkyl” group and “amine substituted alkyl” group. Therefore, this claim is rejected for indefiniteness. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1, 6, 11, and 24 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Lee et al. “Crystal structures of spleen tyrosine kinase in complex with novel inhibitors: structural insights for design of anticancer drugs,” The FEBS Journal 283 (2016) 3613–3625 published 2016. Lee teaches many SYK inhibitors that anticipate the claims, including O178 that has a hydrogen bond to Asp512. The structure is: PNG media_image9.png 360 354 media_image9.png Greyscale O178 anticipates claims 1, 6 (bulky para substituent), 11 (rigid), 24 (hydrogen bond to Asp512). Claim Rejections - 35 USC § 102 Claims 1-2, 9, 11, 15, 24, and 36-37 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Mitchell WO2010068257A1 published 6/17/2010. Mitchell teaches SYK inhibitors and methods of treating disease with them including: PNG media_image10.png 342 644 media_image10.png Greyscale This compound anticipated claims 1, 2, 9 (substituted A with 2 methoxy groups), 11 (the B ring is rigid, and the B ring is a substituted pyrazine), 15, 24 (the B ring is capable of a hydrogen bond). The compounds are taught to be pharmaceuticals, and in compositions for use, therefore claim 36 is anticipated. Claim 37 requires formulants, cremophor is taught by Mitchell on page 249. Claim Rejections - 35 USC § 102 Claims 1 and 18 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Ericsson WO2007117465A2 published 10/18/2007. Ericsson teaches kinase inhibitors and methods of treating disease with them including: PNG media_image11.png 406 769 media_image11.png Greyscale This compound anticipates claims 1 and 18 (requires the C ring is an indole. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 1-2, 9, 11, 15, 24, 36-37 and claims 41, 42, 44, 47, 49 and 50 are rejected under 35 U.S.C. 103 as being unpatentable over Mitchell WO2010068257A1 published 6/17/2010 (which anticipates claims 1-2, 9, 11, 15, 24, and 36-37) in view of Turrini WO2016168444A1 published 10/20/2016. Claims 41, 42, 44, 47, 49 and 50 are directed to treating RBC mediated disease with selective Syk Inhibitors. Mitchell teaches selective Syk inhibitors having structure that anticipates claims 1-2, 9, 11, 15, 24, 36-37. Turrini teaches using selective Syk inhibitors for treating RBC mediated diseases including the those instantly claimed. This includes thalassemia. It is obvious to use the specific Syk inhibitors taught by Mitchell in place of the generic “compounds that inhibit the spleen tyrosine kinse (SYK)” as taught by Turrini as the activity drives the effect, as such a person would use the compounds of Mitchell because they are taught to have the required activity to provide efficacy in this disease treatment. Instant claims 49-50 require an additional active including fostamatinib. Turrini teaches that fostamatinib can be used in combination, see [0012], [0016], and [0023]. As such it is obvious to use the Compounds of Mitchell in combination with fostamatinib, as this is a simple substitution that would be expected to interdict the same pathway. Allowable Subject Matter Claims 25 is objected to as being dependent upon a rejected base claim but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Claims 16, 30, and 32 would be allowable if rewritten or amended to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph, set forth in this Office action. Conclusion No claims allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICHAEL J SCHMITT whose telephone number is (571)270-7047. The examiner can normally be reached M-F 8-6 MidDay Flex. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Lundgren can be reached at 571-272-5541. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MICHAEL J SCHMITT/Examiner, Art Unit 1629 /JEFFREY S LUNDGREN/Supervisory Patent Examiner, Art Unit 1629
Read full office action

Prosecution Timeline

Sep 13, 2024
Application Filed
Nov 10, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12797395
TREPROSTINIL ADMINISTRATION BY INHALATION
4y 1m to grant Granted Nov 17, 2026
Patent 12797358
PLANT-DERIVED SMALL MOLECULES AS MARBURG VIRUS INHIBITORS
3y 0m to grant Granted Nov 17, 2026
Patent 12788747
THERAPEUTIC DRUG FOR DISEASES RELATED TO ENDOPLASMIC RETICULUM CELL DEATH IN CORNEAL ENDOTHELIUM
4y 5m to grant Granted Nov 10, 2026
Patent 12780783
Glucose and Lipid Metabolism Regulating Agents, Pharmaceutical Compositions Comprising the Same, and Treatment Methods
2y 4m to grant Granted Nov 03, 2026
Patent 12773386
Hematocrit Modulation Through Needle Assisted Jet Injection of Testosterone
4y 12m to grant Granted Oct 27, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
57%
Grant Probability
77%
With Interview (+19.9%)
2y 10m (~8m remaining)
Median Time to Grant
Low
PTA Risk
Based on 664 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month